⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5771268 | 1.00 | — | — | |
| SCHEMBL15919925 | 0.93 | NOS3 (0.48) | — | |
| SCHEMBL8561861 | 0.93 | NOS3 (0.48) | — | |
| SCHEMBL16854923 | 0.93 | NOS3 (0.48) | — | |
| SCHEMBL2598810 | 0.91 | NOS1 (0.50) | — | |
| SCHEMBL5026142 | 0.88 | NOS1 (0.48) | — | |
| SCHEMBL5832697 | 0.86 | NOS3 (0.47) | — | |
| SCHEMBL11842283 | 0.86 | NOS3 (0.45) | — | |
| SCHEMBL6335314 | 0.86 | NOS3 (0.45) | — | |
| SCHEMBL23917218 | 0.84 | NOS3 (0.43) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 108 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4216951-B1 | KRAS G12D INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2026-04-01 | — | — | EP | claimed |
| US-20250000863-A1 | COMBINATION THERAPIES OF KRAS G12D INHIBITORS WITH SOS1 INHIBITORS | MIRATI THERAPEUTICS, INC | 2025-01-02 | — | — | US | claimed |
| US-20240423984-A1 | COMBINATION THERAPIES OF KRAS G12D INHIBITORS WITH SHP-2 INHIBITORS | MIRATI THERAPEUTICS, INC | 2024-12-26 | — | — | US | claimed |
| US-20240408099-A1 | COMBINATION THERAPIES OF KRAS G12D INHIBITORS WITH Pan ErbB FAMILY INHIBITORS | MIRATI THERAPEUTICS, INC | 2024-12-12 | — | — | US | claimed |
| EP-4412717-A1 | COMBINATION THERAPIES OF KRAS G12D INHIBITORS WITH PAN ERBB FAMILY INHIBITORS | Mirati Therapeutics, Inc. (US) | 2024-08-14 | — | — | EP | claimed |
| EP-4412719-A1 | COMBINATION THERAPIES OF KRAS G12D INHIBITORS WITH SHP-2 INHIBITORS | Mirati Therapeutics, Inc. (US) | 2024-08-14 | — | — | EP | claimed |
| EP-4412718-A1 | COMBINATION THERAPIES OF KRAS G12D INHIBITORS WITH SOS1 INHIBITORS | Mirati Therapeutics, Inc. (US) | 2024-08-14 | — | — | EP | claimed |
| CN-114615981-B | KRAS G12D inhibitors | 米拉蒂治疗股份有限公司 | 2024-04-12 | — | — | CN | claimed |
| CN-117651700-A | 2-aminobenzothiazole compounds and methods of use | 安进公司 | 2024-03-05 | — | — | CN | claimed |
| US-20230357277-A1 | KRAS G12D INHIBITORS | ARRAY BIOPHARMA INC. | 2023-11-09 | — | — | US | claimed |
| EP-4216951-A1 | KRAS G12D INHIBITORS | Mirati Therapeutics, Inc. (US) | 2023-08-02 | — | — | EP | claimed |
| WO-2023059596-A1 | COMBINATION THERAPIES OF KRAS G12D INHIBITORS WITH Pan ErbB FAMILY INHIBITORS | Mirati Therapeutics, Inc. (US) | 2023-04-13 | — | — | WO | claimed |
| WO-2023059597-A1 | COMBINATION THERAPIES OF KRAS G12D INHIBITORS WITH SOS1 INHIBITORS | Mirati Therapeutics, Inc. (US) | 2023-04-13 | — | — | WO | claimed |
| WO-2023059598-A1 | COMBINATION THERAPIES OF KRAS G12D INHIBITORS WITH SHP-2 INHIBITORS | Mirati Therapeutics, Inc. (US) | 2023-04-13 | — | — | WO | claimed |
| US-11453683-B1 | KRas G12D inhibitors | Mirati Therapeutics, Inc. (US) | 2022-09-27 | — | — | US | claimed |
| EP-4021444-A1 | KRAS G12D INHIBITORS | Mirati Therapeutics, Inc. (US) | 2022-07-06 | — | — | EP | claimed |
| CN-114615981-A | KRAS G12D inhibitors | 米拉蒂治疗股份有限公司 | 2022-06-10 | — | — | CN | claimed |
| WO-2022066646-A1 | KRAS G12D INHIBITORS | Mirati Therapeutics, Inc. (US) | 2022-03-31 | — | — | WO | claimed |
| WO-2021041671-A1 | KRAS G12D INHIBITORS | Mirati Therapeutics, Inc. (US) | 2021-03-04 | — | — | WO | claimed |
| US-12630566-B2 | KRas G12D inhibitors | Mirati Therapeutics, Inc. (US) | 2026-05-19 | — | — | US | disclosed |
| US-20260109714-A1 | PYRIMIDINE-FUSED RING COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | GENFLEET THERAPEUTICS SHANGHAI INC (CN) | 2026-04-23 | — | — | US | disclosed |
| EP-4216951-B1 | KRAS G12D INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2026-04-01 | — | — | EP | disclosed |
| WO-2025217015-A1 | COMBINATION THERAPIES USING PRMT5 INHIBITORS AND KRAS G12D INHIBITORS FOR THE TREATMENT OF CANCER | Mirati Therapeutics, Inc. (US) | 2025-10-16 | — | — | WO | disclosed |
| US-20250312343-A1 | COMBINATION THERAPIES USING PRMT5 INHIBITORS AND KRAS G12D INHIBITORS FOR THE TREATMENT OF CANCER | Mirati Therapeutics, Inc. (US) | 2025-10-09 | — | — | US | disclosed |
| EP-4592295-A1 | PYRIMIDINE-FUSED RING COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Genfleet Therapeutics (Shanghai) Inc. (CN) | 2025-07-30 | — | — | EP | disclosed |
| US-20250186456-A1 | PYRIMIDINE-FUSED CYCLIC COMPOUND AND PREPARATION METHOD AND USE THEREOF | GENFLEET THERAPEUTICS (SHANGHAI) INC. (CN) | 2025-06-12 | — | — | US | disclosed |
| EP-4540226-A1 | BIFUNCTIONAL MOLECULES FOR TARGETED PROTEIN DEGRADATION | Amphista Therapeutics Ltd (GB) | 2025-04-23 | — | — | EP | disclosed |
| US-12281127-B2 | Pyrido[4,3-d]pyrimidine compounds | PFIZER INC. (US) | 2025-04-22 | — | — | US | disclosed |
| US-20240309020-A1 | KRAS G12D INHIBITORS | ARRAY BIOPHARMA INC. | 2024-09-19 | — | — | US | disclosed |
| CN-115151252-B | Iron death inhibitor-diarylamine acetamides | 维泰瑞隆有限公司 | 2024-08-27 | — | — | CN | disclosed |
| US-20240270758-A1 | PYRIDINO-OR PYRIMIDO-CYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | ZHEJIANG GENFLEET THERAPEUTICS CO., LTD. (CN) | 2024-08-15 | — | — | US | disclosed |
| US-20240254129-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | KUMQUAT BIOSCIENCES INC. | 2024-08-01 | — | — | US | disclosed |
| US-20240239788-A1 | SMALL MOLECULE INHIBITORS OF KRAS G12D MUTANT | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2024-07-18 | — | — | US | disclosed |
| EP-4397664-A1 | PYRIMIDINE-FUSED CYCLIC COMPOUND AND PREPARATION METHOD AND USE THEREOF | Genfleet Therapeutics (Shanghai) Inc. (CN) | 2024-07-10 | — | — | EP | disclosed |
| US-20240174691-A1 | PYRIMIDINE-FUSED CYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | GENFLEET THERAPEUTICS (SHANGHAI) INC. (CN) | 2024-05-30 | — | — | US | disclosed |
| US-11964989-B2 | KRas G12D inhibitors | Mirati Therapeutics, Inc. (US) | 2024-04-23 | — | — | US | disclosed |
| CN-117916245-A | Pyrimidine ring compound and preparation method and application thereof | 劲方医药科技(上海)有限公司 | 2024-04-19 | — | — | CN | disclosed |
| CN-114615981-B | KRAS G12D inhibitors | 米拉蒂治疗股份有限公司 | 2024-04-12 | — | — | CN | disclosed |
| CN-116057059-B | Deuterated compounds useful as KRAS G12D inhibitors | 南京燧坤智能科技有限公司 | 2024-03-08 | — | — | CN | disclosed |
| EP-4332105-A1 | PYRIDINO- OR PYRIMIDO-CYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | Genfleet Therapeutics (Shanghai) Inc. (CN) | 2024-03-06 | — | — | EP | disclosed |
| EP-4329888-A1 | 2-AMINOBENZOTHIAZOLE COMPOUNDS AND METHODS OF USE THEREOF | Amgen Inc. (US) | 2024-03-06 | — | — | EP | disclosed |
| CN-117651700-A | 2-aminobenzothiazole compounds and methods of use | 安进公司 | 2024-03-05 | — | — | CN | disclosed |
| EP-4310091-A1 | PYRIMIDINE-FUSED CYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | Genfleet Therapeutics (Shanghai) Inc. (CN) | 2024-01-24 | — | — | EP | disclosed |
| WO-2023242597-A1 | BIFUNCTIONAL MOLECULES FOR TARGETED PROTEIN DEGRADATION | AMPHISTA THERAPEUTICS LIMITED (GB) | 2023-12-21 | — | — | WO | disclosed |
| EP-4291199-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | Kumquat Biosciences Inc. (US) | 2023-12-20 | — | — | EP | disclosed |
| CN-117222650-A | Pyridine or pyrimido-ring compound, preparation method and medical application thereof | 劲方医药科技(上海)有限公司 | 2023-12-12 | — | — | CN | disclosed |
| CN-117043167-A | Pyrimidine ring compound and preparation method and application thereof | 劲方医药科技(上海)有限公司 | 2023-11-10 | — | — | CN | disclosed |
| US-20230357277-A1 | KRAS G12D INHIBITORS | ARRAY BIOPHARMA INC. | 2023-11-09 | — | — | US | disclosed |
| US-20230339976-A1 | KRAS G12D INHIBITORS | Mirati Therapeutics, Inc. | 2023-10-26 | — | — | US | disclosed |
| US-20230279025-A1 | KRAS G12D INHIBITORS | ARRAY BIOPHARMA INC. | 2023-09-07 | — | — | US | disclosed |
| EP-4216951-A1 | KRAS G12D INHIBITORS | Mirati Therapeutics, Inc. (US) | 2023-08-02 | — | — | EP | disclosed |
| EP-4192585-A1 | KRAS G12D INHIBITORS | Mirati Therapeutics, Inc. (US) | 2023-06-14 | — | — | EP | disclosed |
| EP-4182313-A1 | KRAS G12D INHIBITORS | Mirati Therapeutics, Inc. (US) | 2023-05-24 | — | — | EP | disclosed |
| CN-116057059-A | Deuterated compounds useful as KRAS G12D inhibitors | 南京燧坤智能科技有限公司 | 2023-05-02 | — | — | CN | disclosed |
| US-20230077225-A1 | KRAS G12D INHIBITORS | Mirati Therapeutics, Inc. | 2023-03-09 | — | — | US | disclosed |
| WO-2022262838-A1 | DEUTERATED COMPOUNDS USEFUL AS KRAS G12D INHIBITORS | SILEXON AI TECHNOLOGY CO., LTD. (CN) | 2022-12-22 | — | — | WO | disclosed |
| WO-2022232332-A1 | 2-AMINOBENZOTHIAZOLE COMPOUNDS AND METHODS OF USE THEREOF | AMGEN INC. (US) | 2022-11-03 | — | — | WO | disclosed |
| US-11453683-B1 | KRas G12D inhibitors | Mirati Therapeutics, Inc. (US) | 2022-09-27 | — | — | US | disclosed |
| WO-2022173870-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | KUMQUAT BIOSCIENCES INC. (US) | 2022-08-18 | — | — | WO | disclosed |
| EP-4021444-A1 | KRAS G12D INHIBITORS | Mirati Therapeutics, Inc. (US) | 2022-07-06 | — | — | EP | disclosed |
| CN-114615981-A | KRAS G12D inhibitors | 米拉蒂治疗股份有限公司 | 2022-06-10 | — | — | CN | disclosed |
| WO-2022066646-A1 | KRAS G12D INHIBITORS | Mirati Therapeutics, Inc. (US) | 2022-03-31 | — | — | WO | disclosed |
| WO-2022031678-A1 | KRAS G12D INHIBITORS | Mirati Therapeutics, Inc. (US) | 2022-02-10 | — | — | WO | disclosed |
| WO-2022015375-A1 | KRAS G12D INHIBITORS | Mirati Therapeutics, Inc. (US) | 2022-01-20 | — | — | WO | disclosed |
| EP-3368524-B1 | HETEROARYLCARBOXAMIDE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2021-08-18 | — | — | EP | disclosed |
| WO-2021041671-A1 | KRAS G12D INHIBITORS | Mirati Therapeutics, Inc. (US) | 2021-03-04 | — | — | WO | disclosed |
| US-10640486-B2 | Heteroarylcarboxamide derivatives as plasma kallikrein inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2020-05-05 | — | — | US | disclosed |
| US-20180319771-A1 | HETEROARYLCARBOXAMIDE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-11-08 | — | — | US | disclosed |
| EP-3368524-A1 | HETEROARYLCARBOXAMIDE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2018-09-05 | — | — | EP | disclosed |
| WO-2017072021-A1 | HETEROARYLCARBOXAMIDE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-05-04 | — | — | WO | disclosed |
| EP-2877446-B9 | NEW ANTIFIBRINOLYTIC COMPOUNDS | PROYECTO DE BIOMEDICINA CIMA S L (ES) | 2017-01-25 | — | — | EP | disclosed |
| EP-2246347-B1 | DICYCLOAZAALKANE DERIVATES, PREPARATION PROCESSES AND MEDICAL USES THEREOF | SHANGHAI HENGRUI PHARM CO LTD (CN) | 2016-09-28 | — | — | EP | disclosed |
| EP-2877446-B1 | NEW ANTIFIBRINOLYTIC COMPOUNDS | PROYECTO BIOMEDICINA CIMA SL (ES) | 2016-09-14 | — | — | EP | disclosed |
| US-9440989-B2 | Antifibrinolytic compounds | PROYECTO DE BIOMEDICINA CIMA, S.L. (ES) | 2016-09-13 | — | — | US | disclosed |
| US-9096603-B2 | 1-heterocyclyl-1,5-dihydro-pyrazolo[3,4-D] pyrimidin-4-one derivatives and their use as PDE9A modulators | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-08-04 | — | — | US | disclosed |
| WO-2015104343-A1 | NEW ANTIFIBRINOLYTIC COMPOUNDS | PROYECTO DE BIOMEDICINA CIMA, S.L. (ES) | 2015-07-16 | — | — | WO | disclosed |
| US-20150175618-A1 | NEW ANTIFIBRINOLYTIC COMPOUNDS | PROYECTO DE BIOMEDICINA CIMA, S.L. (ES) | 2015-06-25 | — | — | US | disclosed |
| EP-2877446-A1 | NEW ANTIFIBRINOLYTIC COMPOUNDS | Proyecto de Biomedicina Cima, S.L. (ES) | 2015-06-03 | — | — | EP | disclosed |
| US-20140073641-A1 | 1-HETEROCYCLYL-1,5-DIHYDRO-PYRAZOLO[3,4-D] PYRIMIDIN-4-ONE DERIVATIVES AND THEIR USE AS PDE9A MODULATORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-03-13 | — | — | US | disclosed |
| WO-2014012964-A1 | NEW ANTIFIBRINOLYTIC COMPOUNDS | PROYECTO DE BIOMEDICINA CIMA, S.L. (ES) | 2014-01-23 | — | — | WO | disclosed |
| US-8623879-B2 | 1-heterocyclyl-1,5-dihydro-pyrazolo[3,4-D] pyrimidin-4-one derivates and their use as PDE9A modulators | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-01-07 | — | — | US | disclosed |
| US-20110237538-A1 | TREATMENT OF LYSOSOMAL STORAGE DISORDERS AND OTHER PROTEOSTATIC DISEASES | SUMMIT CORPORATION PLC (GB) | 2011-09-29 | — | — | US | disclosed |
| US-20110237538-A1 | TREATMENT OF LYSOSOMAL STORAGE DISORDERS AND OTHER PROTEOSTATIC DISEASES | SUMMIT CORPORATION PLC (GB) | 2011-09-29 | — | — | US | disclosed |
| US-20110195929-A1 | COMPOUNDS FOR THE TREATMENT OF FLAVIVIRAL INFECTIONS | SUMMIT CORPORATION PLC (GB) | 2011-08-11 | — | — | US | disclosed |
| US-20110195929-A1 | COMPOUNDS FOR THE TREATMENT OF FLAVIVIRAL INFECTIONS | SUMMIT CORPORATION PLC (GB) | 2011-08-11 | — | — | US | disclosed |
| US-20110184000-A1 | 1-HETEROCYCLYL-1,5-DIHYDRO-PYRAZOLO[3,4-D] PYRIMIDIN-4-ONE DERIVATES AND THEIR USE AS PDE9A MODULATORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-07-28 | — | — | US | disclosed |
| US-20110086860-A1 | COMPOUND | KIMURA TEIJI | 2011-04-14 | — | — | US | disclosed |
| US-7880009-B2 | Alzheimer's disease, senile dementia, Down syndrome or amyloidosis; (E)-N-biphenyl-3-ylmethyl-3-(3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl)acrylamide for example; imidazolyl-functional compounds inhibit production of Amyloid beta 40 and Amyloid beta 42 | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-02-01 | — | — | US | disclosed |
| US-7687640-B2 | Cinnamide compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-03-30 | — | — | US | disclosed |
| US-7667041-B2 | Alzheimer's disease, senile dementia, Down syndrome or amyloidosis; 3E)-1-[(1S)-1-(4-fluorophenyl)ethyl]-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]piperidin-2-one; imidazolyl-functional compounds inhibit production of Amyloid beta 40 and Amyloid beta 42; low hygroscopicity; good solubility | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-02-23 | — | — | US | disclosed |
| US-20090286777-A1 | 5,6,Fused Pyrrolidine Compounds Useful as Tachykinin Receptor Antagonists | MERCK SHARP & DOHME CORP. | 2009-11-19 | — | — | US | disclosed |
| US-20090281310-A1 | 3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzaldehyde; inhibits production of A beta 40 and A beta 42 from amyloid precursor protein ; Alzheimer's disease and Down syndrome | EISAI R&D MANAGEMENT CO., LTD. | 2009-11-12 | — | — | US | disclosed |
| US-20090263322-A1 | OCTAHYDRO-INDOLIZINE AND QUINOLIZINE AND HEXAHYDRO-PYRROLIZINES | APODACA RICHARD | 2009-10-22 | — | — | US | disclosed |
| US-20090203697-A1 | HETEROCYCLIC TYPE CINNAMIDE DERIVATIVE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-08-13 | — | — | US | disclosed |
| US-20090042854-A1 | Hexahydro-3H-Pyrrolizin-3-Ones Useful as Tachykinin Receptor Antagonists | MERCK SHARP & DOHME CORP. | 2009-02-12 | — | — | US | disclosed |
| US-20090042854-A1 | Hexahydro-3H-Pyrrolizin-3-Ones Useful as Tachykinin Receptor Antagonists | MERCK SHARP & DOHME CORP. | 2009-02-12 | — | — | US | disclosed |
| EP-1978965-A2 | HEXAHYDRO-3H-PYRROLIZIN-3-ONES USEFUL AS TACHYKININ RECEPTOR ANTAGONISTS | Merck & Co., Inc. (US) | 2008-10-15 | — | — | EP | disclosed |
| US-20080187907-A1 | Catalytic Production of Biomakers From Biological Materials | BRIGHAM YOUNG UNIVERSITY | 2008-08-07 | — | — | US | disclosed |
| US-20080187907-A1 | Catalytic Production of Biomakers From Biological Materials | BRIGHAM YOUNG UNIVERSITY | 2008-08-07 | — | — | US | disclosed |
| US-7390801-B2 | Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds | ATHENA NEUROSCIENCES, INC. (US) | 2008-06-24 | — | — | US | disclosed |
| US-7390801-B2 | Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds | ATHENA NEUROSCIENCES, INC. (US) | 2008-06-24 | — | — | US | disclosed |
| US-20080070902-A1 | Cinnamide Compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2008-03-20 | — | — | US | disclosed |
| WO-2007136570-A2 | 5,6-FUSED PYRROLIDINE COMPOUNDS USEFUL AS TACHYKININ RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2007-11-29 | — | — | WO | disclosed |
| US-20070203108-A1 | Alzheimer's disease; 5-{N'-(4-thianaphthenacetyl)-L-alaninyl}-amino-7-methyl-5,7-dihydro-6H-dibenz[b,d]azepin-6-one | THORSETT EUGENE D | 2007-08-30 | — | — | US | disclosed |
| US-20070203108-A1 | Alzheimer's disease; 5-{N'-(4-thianaphthenacetyl)-L-alaninyl}-amino-7-methyl-5,7-dihydro-6H-dibenz[b,d]azepin-6-one | THORSETT EUGENE D | 2007-08-30 | — | — | US | disclosed |
| WO-2007087224-A2 | HEXAHYDRO-3H-PYRROLIZIN-3-ONES USEFUL AS TACHYKININ RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2007-08-02 | — | — | WO | disclosed |
| US-4800207-A | Hexahydropyrrolizine compounds useful as analgesics | MCNEILAB, INC. (US) | 1989-01-24 | — | — | US | disclosed |
| US-4581462-A | Pyrrolizidine-3-ones | THE UPJOHN COMPANY (US) | 1986-04-08 | — | — | US | disclosed |
| US-4581462-A | Pyrrolizidine-3-ones | THE UPJOHN COMPANY (US) | 1986-04-08 | — | — | US | disclosed |